**Background**
Protein arginine methyltransferases (PRMTs) play a critical role in regulating gene expression and signal transduction through the methylation of arginine residues on various proteins. Among these, PRMT5 is a key enzyme involved in the methylation of histone H4R3, which is often dysregulated in various malignancies and inflammatory conditions. Specifically, PRMT5 activity is frequently hijacked to drive the initiation and maintenance of B-cell transformation, making it a promising target for cancer therapy. Furthermore, PRMT5 inhibition has shown potential in suppressing aberrant T cell responses in autoimmune diseases. In this context, we will introduce a potent and selective PRMT5 inhibitor – CMP-5.
**Definition**
CMP-5 is a potent, specific, and selective PRMT5 inhibitor that selectively blocks S2Me-H4R3 by inhibiting PRMT5 methyltransferase activity on histone preparations. According to the CMP-5 description, it displays no activity against PRMT1, PRMT4, and PRMT7 enzymes.
**In Vitro Studies**
The CMP-5 biological activity has been extensively evaluated in various cell models. In vitro studies demonstrate that CMP-5 (0-100 μM; 24-72 hours) is selectively toxic to lymphoma cells while showing limited toxicity to normal resting B lymphocytes, even after prolonged incubation. Furthermore, CMP-5 prevents Epstein-Barr virus (EBV)-driven B-lymphocyte transformation without affecting normal B cells. In 60A cells, treatment with CMP-5 (40 μM; 24 hours) significantly decreases the expression of p-BTK and pY(416) SRC compared to DMSO-treated groups. Regarding immune response modulation, CMP-5 (0-40 μM; 24 hours) preferentially suppresses the proliferation of human Th1 cells over Th2 cells, with IC50 values of 26.9 μM and 31.6 μM, respectively. Additionally, CMP-5 (25 μM; 24 hours) alone inhibits mouse Th1 cell proliferation by 91%, although this effect can be partially reversed by the addition of IL-2 in a dose-dependent manner. In conclusion, CMP-5 is a highly selective PRMT5 inhibitor that holds significant potential for research in CMP-5 cancer and inflammatory T cell response studies.
Keywords
CMP-5, 880813-42-3, CMP5, CMP 5, Histone Methyltransferase, lymphoma, cells, Th1, Th2, 60A, EBV, PRMT5, B-lymphocyte, S2Me-H4R3, Inhibitor, inhibitor, inhibit
References
[1] Alinari L, et al. Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.Blood. 2015 Apr 16;125(16):2530-43.
[2] Webb LM, et al. PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis. J Immunol. 2017 Feb 15;198(4):1439-1451.